Regulatory Approval

18 March 2009


                           ECO Animal Health Group plc



          POSITIVE OPINION ON NEW AIVLOSIN®  PRODUCT FOR PIGS IN EUROPE


ECO Animal Health Group plc is pleased to announce that its subsidiary ECO
Animal Health Limited (ECO) has received a positive opinion from the Committee
for Medicinal Products for Veterinary Use (CVMP) of the European Medicines
Agency (EMEA) for Aivlosin®         625 mg/g granules for oral solution for
medicated drinking water for pigs.

This positive opinion will allow Aivlosin®, ECO's patented macrolide antibiotic,
to  be  marketed  throughout  Europe for use  in  pigs  for  the  treatment  and
prevention  of ileitis (porcine proliferative enteropathy (PPE)). ECO  estimates
this  market  segment to be worth in the region of US $30 million per  annum  at
manufacturer level.

Aivlosin®  granules  for  oral  solution  dissolve  readily  in  drinking  water
providing a simple solution for the accurate and simultaneous treatment of large
numbers of pigs.

Peter Lawrence, Chairman of ECO Animal Health group plc, commented:
"This  important  positive opinion marks further progress  in  ECO's  continuing
development  of Aivlosin® as a global veterinary product. It will  significantly
extend  the  sales  and  marketing reach of Aivlosin®, which  is  used  for  the
treatment of respiratory and enteric diseases in pigs and poultry".


Contacts:
ECO  Animal Health Group plc                           Marc Loomes     020  8447
8899

Spiro  Financial                                    Anthony Spiro      020  8336
6196

Cenkos Securities plc                                       Stephen Keys     020
7397 8926
(Nominated  Adviser)                                                         Liz
Bowman     020 7397 8928

ECO  Animal  Health Group plc is a leader in the development,  registration  and
marketing of pharmaceutical products for animals. Our products for these  global
growth markets promote well-being. Our financial goals are achieved through  the
careful  and  responsible  application of science  to  generate  value  for  our
shareholders.